PhD Scientific Days 2024

Budapest, 9-10 July 2024

Theoretical and Translational Medicine III.

Early nutrition is safe and does not increase complications after upper gastrointestinal bleeding: a systematic review and meta-analysis of randomized controlled trials


Mahmoud Obeidat1, Brigitta Teutsch1,2, Diana-Elena Floria1,5, Dániel Sándor Veres1,4, Péter Hegyi1,2,3, Bálint Erőss1,2,3
1: Centre for Translational Medicine, Semmelweis University, Budapest 1085, Hungary
2: Institute for Translational Medicine, Medical School, University of Pécs, Pécs 7623, Hungary
3: Institute of Pancreatic Diseases, Semmelweis University, Budapest 1083, Hungary
4: Department of Biophysics and Radiation Biology, Semmelweis University, Budapest 1085, Hungary
5: Grigore T. Popa University of Medicine and Pharmacy, Iași 700115, Romania

Text of the abstract

Despite a lack of evidence, patients are often not fed for 48 to 96 hours after upper gastrointestinal bleeding (UGIB); however, many trials have demonstrated the benefits of early nutrition (EN).

We conducted a meta-analysis of randomized controlled trials (RTCs) to evaluate the outcomes of EN compared to delayed nutrition (DN) after UGIB.

The protocol was registered on PROSPERO (CRD42022372306). PubMed, Embase, CENTRAL, Scopus, and Web of Science were searched on the 27th of April 2024 to identify eligible RCTs. The primary outcomes were early (within 7 days) and late (within 30-42 days) mortality and rebleeding. Pooled risk ratios (RR), mean differences (MD), and corresponding 95% confidence intervals (CI) were calculated using a random-effects model.

A total of 10 trials with 1,051 patients were included in the analysis. Early mortality was not significantly different between the two groups (RR: 1.20, CI: 0.85 – 1.71, I2 = 0%), whereas late mortality was reduced to a clinically relevant extent in the EN group (RR: 0.61, CI: 0.35 – 1.06, I2 = 0%). When comparing the two groups, we found no significant difference in terms of early and late rebleeding (RR: 1.04, CI: 0.66 – 1.63, I2 = 0% and RR: 1.16, CI: 0.63 – 2.13, I2 = 0%, respectively). Our analysis also showed that the length of hospital stay was reduced in the EN group compared to the DN group (MD: - 1.22 days, CI: - 2.43 to - 0.01, I2 = 94%).

Compared with DN, EN (within 24 hours) appears to be a safe intervention and could reduce the length of hospital stay without increasing the risk of complications after UGIB.